Compared with ER+/PR+ and HER2+ BC patients benefiting from endocrine and targeted therapies with chemotherapy, triple‐negative, or basal BC patients have poorer prognoses due to limited treatment options.4, 5, 6. Here, ERBB2 is linked to breast cancer.